IA
NTLA icon

IFG Advisory’s Intellia Therapeutics NTLA Stock Holding History

IFG Advisory’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.91K Buy
+586
New +$8.2K ﹤0.01% 1845

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

IFG Advisory's NTLA Position: Q2 2026 in Review

IFG Advisory opened a new position in Intellia Therapeutics (NTLA) in Q2 2026: 586 shares worth $9.91K. The stake represents ﹤0.01% of the portfolio and ranks #1845 among its holdings.

327 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • IFG Advisory held 586 shares of Intellia Therapeutics worth $9.91K as of Q2 2026.
  • Intellia Therapeutics was a new IFG Advisory position in Q2 2026.
  • Intellia Therapeutics made up ﹤0.01% of IFG Advisory's portfolio in Q2 2026, its #1845 holding.
  • 327 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on IFG Advisory's 13F filing for Q2 2026, filed 14 Aug 2026.